Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015 ('the Listing Regulations'), we wish ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Veerhealth Care's board approved unaudited financial results for Q3 FY26 and 9M FY26 on February 14, 2026. Revenue from operations for 9M FY26 rose to Rs. 1,572.30 lakhs from Rs. 1,105.06 lakhs in 9M FY25, a YoY growth of around 42%. Profit after tax for 9M FY26 jumped to Rs. 89.75 lakhs from Rs. 50.26 lakhs, up about 79% YoY. However, Q3 FY26 standalone revenue fell sharply to Rs. 389.89 lakhs compared with Rs. 725.79 lakhs in Q3 FY25, though the company swung to a Q3 profit of Rs. 7.05 lakhs from a loss of Rs. 40.48 lakhs. The statutory auditor issued a clean limited review report with no adverse observations. The company operates in a single segment – Healthcare Pharma Products.
The strong 9M YoY growth in both revenue and profit is positive for shareholders, but the steep Q3 revenue decline warrants caution. Investors should watch whether the Q3 weakness is a one-off or signals slowing momentum, even as full-period profitability has clearly improved.